Viatris Inc

Company facts

Industry

Pharmaceutical Preparations

Headquarters

Canonsburg, Pennsylvania

Most recent report

10-Q, filed Aug 6, 2026

Incorporated

Delaware

Filings on record

536 filings

On EDGAR

CIK 1792044

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 2 of 9 sections worth reading, with 1 positive, 5 notable, and 12 negative flags.

• Part I

  Full of company-specific numbers: opioid accrual, litigation, restructuring, debt moves.
  Notable

  • A $177.8M write-down was taken on Tyrvaya intangible assets, classified as held for sale (sold for $30M cash + $70M milestones).
  • Repurchased 9.4M shares for $150M in Q2 2026; another $120M after period, total $1.27B under $2B program.
  • Issued €650M of 4.25% Senior Notes due 2033 to repay $1.675B 2026 notes and for general purposes.
  Negative

  • Biocon equity shares sold on July 14, 2026 for ~$380M, recording a $27.4M loss; shares fell after lockup.
  • Debt maturity wall: $1.72B due 2027, $1.61B due 2028, plus $7.9B thereafter. Total notional $12.94B.
  • 2026 restructuring program expects $700-850M total charges; $105.2M booked so far, up to 10% workforce cut.
  • Nashik fire caused $86.8M in charges in H1 2026; FDA issued Form 483; product supply expected to be hit.
  • Pfizer sent a letter in June 2026 demanding 57% of opioid losses; Viatris disagrees payment is owed.
  • Uncertain tax positions reserve of $264.2M; French tax court win appealed; Italian tax assessments challenged.
  • Drug pricing litigation has $50M accrued; a trial in Sept 2026 asserts ~$1B damages (trebled) against Viatris.
  • Securities litigation accrual of $60M; $58M insurance receivable booked. New Indore class action filed.
  • Opioid settlement accrual of $281.3M at June 30, 2026, up to $335M total over nine years.

• Management's Discussion (Item 2)

  Real results, manufacturing disruptions, restructuring, and opioid dispute – all company-specific.
  Positive

  • Adjusted gross margin held at 57% for Q2 2026 and improved to 57% for H1 2026 from 56% in H1 2025.
  Notable

  • Share repurchases slowed: $150M in H1 2026 vs $350.4M in H1 2025; $120.2M bought after quarter end.
  • Operating cash flow $770.1M in H1 2026, up $14.9M vs H1 2025; no borrowings on $3.5B revolver or $600M receivables facility.
  Negative

  • FDA warning letter and import alert at Indore facility still in effect; 11 products barred from U.S.
  • Legal accruals $453M at June 30, 2026, up from $450.8M at March 31, 2026.
  • Pfizer requested 57% of opioid losses; Viatris disagrees payment is owed – dispute could be material.

What changed: Jun 2026 vs. Mar 2026

About 13% of VTRS's Jun 2026 10-Q is new information. 76 paragraphs were added, 188 changed, and 21 removed. Below are the most important lines SECSift identified.

• Item 2 101
• Part I 98
• Item 5 3
• Item 4 2